CIK 0001812364
- Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $119,185,588
- in 10 filings, $2.7M under 10b5-1 plans
Net −$119,185,588. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-09 | Murcko Mark Director | Grant or award · Stock Option (Right to Buy) | +32,947 | 32,947 | ||
| 2025-06-06 | Murcko Mark Director | Grant or award · Stock Option (Right to Buy) | +136,681 | 136,681 | ||
| 2024-06-03 | Murcko Mark Director | Grant or award · Stock Option (Right to Buy) | +102,225 | 102,225 | ||
| 2023-05-31 | Murcko Mark Director | Grant or award · Stock Option (Right to Buy) | +66,055 | 66,055 | ||
| 2022-09-08 | Murcko Mark Director | Sale | −25,000 | $29.95 | $749K | 996,952 |
| 2022-05-27 | Murcko Mark Director | Grant or award · Stock Option (Right to Buy) | +41,597 | 41,597 | ||
| 2021-05-19 | Murcko Mark Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2020-07-20 | Murcko Mark Director | Conversion | +281,617 | 718,123 | ||
| 2020-07-20 | Murcko Mark Director | Conversion | +278,829 | 996,952 | ||
| 2020-07-20 | Murcko Mark Director | Purchase | +25,000 | $20.00 | $500K | 1,021,952 |
| 2020-07-20 | Murcko Mark Director | Conversion · Series A Convertible Preferred Stock | −1,000,000 | 0 | ||
| 2020-07-20 | Murcko Mark Director | Conversion · Series B Convertible Preferred Stock | −990,099 | 0 |
Page 1 of 1 · 12 trades